Bluejay Diagnostics, INC Form 4 insider transactions
Insider transactions: buys and sells by directors, officers and ten percent owners, filed within two business days of the trade.
NASDAQ
Bank Of America Corp /De/ and 2 others reported changes in beneficial ownership of Bluejay Diagnostics, Inc. common stock on July 21, 2026.
NASDAQ
Hrt Financial Lp reported changes in beneficial ownership of Bluejay Diagnostics, Inc. common stock on July 9, 2026.
NASDAQ
Bank of America entities, including Bank of America Corp., Bank of America N.A., and BofA Securities, Inc., have jointly filed a Form 4 indicating their beneficial ownership of Bluejay Diagnostics, Inc. (BJDX) has fallen below the 10% threshold, no longer subjecting them to Section 16 reporting requirements.
NASDAQ
Director Douglas Clark Wurth acquired 12,500 shares of Bluejay Diagnostics common stock in a private placement transaction.
NASDAQ
CEO Indranil Dey acquired 12,500 shares of Bluejay Diagnostics common stock in a private placement transaction.
NASDAQ
Director Donald R. Chase acquired 12,500 shares of Bluejay Diagnostics, Inc. common stock in a private placement.
NASDAQ
Director Fred S. Zeidman acquired 12,500 shares of Bluejay Diagnostics, Inc. common stock in a private placement transaction.
NASDAQ
Director Svetlana Dey acquired 12,500 shares of Bluejay Diagnostics, Inc. common stock in a private placement transaction.